Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.

Abstract	The study of central nervous system (CNS) leukemia has been hampered by the lack of a suitable animal model. We report that severe combined immunodeficiency (SCID) mice invariably develop rapidly progressive fatal CNS leukemia within 3 weeks after intravenous injection of NALM-6 pre-B acute lymphoblastic leukemia (ALL) cells. Colonization of the dura mater and subarachnoid space, usually of the distal spinal cord with occasional extension into the Virchow-Robin spaces of blood vessels subjacent to the meninges, followed involvement of bone marrow in the skull, vertebrae, and, occasionally, the appendicular skeleton. Occult CNS leukemia was detectable by polymerase chain reaction amplification of human DNA as early as 8 days postinoculation of leukemia cells. We used this in vivo model of human CNS leukemia to examine the therapeutic efficacy and toxicity of intrathecally administered B43 (anti-CD19)-pokeweed antiviral protein (PAP), an anti-B-lineage ALL immunotoxin directed against the pan-B-cell antigen CD19/Bp95. Intrathecal therapy with B43 (anti-CD19)-PAP immunotoxin at nontoxic dose levels significantly improved survival of SCID mice and was superior to intrathecal methotrexate therapy.
Authors	R Gunther, L M Chelstrom, L Tuel-Ahlgren, J Simon, D E Myers, F M Uckun
Journal	Blood (Blood) Vol. 85 Issue 9 Pg. 2537-45 (May 01 1995) ISSN: 0006-4971 [Print] United States
PMID	7537120 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Antibodies, Monoclonal Antigens, CD Antigens, CD19 Antigens, Differentiation, B-Lymphocyte DNA, Neoplasm Immunotoxins Plant Proteins Ribosome Inactivating Proteins, Type 1 N-Glycosyl Hydrolases pokeweed antiviral protein Methotrexate
Topics	Animals Antibodies, Monoclonal (administration & dosage, therapeutic use) Antigens, CD (immunology) Antigens, CD19 Antigens, Differentiation, B-Lymphocyte (immunology) Blood-Brain Barrier Bone Marrow (pathology) Cell Movement Central Nervous System (pathology) DNA, Neoplasm (analysis) Drug Evaluation, Preclinical Immunotoxins (administration & dosage, therapeutic use) Injections, Intraperitoneal Injections, Intravenous Injections, Spinal Leukemic Infiltration (drug therapy) Meninges (pathology) Methotrexate (therapeutic use) Mice Mice, SCID N-Glycosyl Hydrolases Neoplasm Transplantation Neoplastic Cells, Circulating Plant Proteins (administration & dosage, therapeutic use) Polymerase Chain Reaction Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, pathology) Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, pathology) Ribosome Inactivating Proteins, Type 1 Specific Pathogen-Free Organisms Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!